GLP-1 weight-loss timeline: what to expect month by month

One of the most common frustrations early on is a mismatch between expectations and the actual shape of the curve: people expect steady, linear loss from week one, and that isn't how these drugs work. Here's a realistic, trial-backed picture of what the timeline actually looks like.

Month 1: modest, and that's expected

In the first month, you're on the lowest, sub-therapeutic starting dose — meant to build tolerance, not to drive weight loss. Expect only modest change in this window, and expect it to be dominated by early water-weight shifts and appetite changes more than dramatic fat loss. This is the month people are most likely to feel discouraged, and it's also the month where the dose you're on isn't yet the dose the trials measured their headline results at.

Months 2–4: the titration climb

As the dose steps up roughly every four weeks — see semaglutide dosing and titration and tirzepatide dosing and titration for the specifics — appetite suppression becomes more pronounced and weight loss typically accelerates. This is also the window where GI side effects are most noticeable, clustered right after each dose increase. Progress in these months is real but still building toward the pattern seen once you're on a stable maintenance dose.

Months 5–12: the maintenance-dose period

Once you're on your target maintenance dose, this is where the pivotal trial data becomes most directly relevant. In STEP-1, participants without diabetes lost a mean of roughly 14.9% of body weight over 68 weeks on semaglutide 2.4 mg, versus about 2.4% on placebo¹. In SURMOUNT-1, tirzepatide produced mean reductions of roughly 15% to 21% over 72 weeks depending on the maintenance dose (5, 10, or 15 mg), versus about 3% on placebo². Those are averages across thousands of participants, not a personal guarantee — individual response varies substantially, and the full molecule-by-molecule comparison, including the direct head-to-head SURPASS-2 trial, is in semaglutide vs tirzepatide: what the trials actually show.

Why the curve isn't a straight line

Most people see faster loss in the middle stretch of treatment and a flattening as they approach their body's new equilibrium at that dose — this is a normal physiological response, not a sign something's wrong, and we cover the biology behind it fully in GLP-1 weight-loss plateaus. Body composition also shifts over this period in ways the scale alone doesn't capture: trial data on tirzepatide's SURMOUNT-1 cohort found meaningful reductions in fat mass alongside some reduction in lean mass, which is why preserving muscle during treatment is worth planning for rather than an afterthought — see preventing muscle loss on a GLP-1.

Beyond a year, and what happens if you stop

For people who stay on treatment past a year, weight loss generally continues more gradually or stabilizes near the level reached during the maintenance-dose period, rather than continuing to accelerate indefinitely. What happens if you stop is its own important question with real trial evidence behind it — the STEP-1 extension found that people who discontinued semaglutide regained a substantial share of the weight they'd lost within roughly a year³. We cover that evidence in full in stopping a GLP-1: regain risk, explained. For women specifically weighing this timeline against a pregnancy plan, GLP-1s and fertility/pregnancy and, for PCOS, GLP-1 for PCOS cover related timing questions worth discussing with your prescriber. This is trial-based context, not a personal prediction — individual results vary, and this isn't medical advice.